Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter T Lansbury

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Nature Medicine|August 10, 2004
Back to the future: the 'old-fashioned' way to new medications for neurodegenerationPeter T Lansbury
Cell|August 23, 2006
Improving synaptic function in a mouse model of ADPeter T Lansbury
Current Opinion in Cell Biology|September 17, 2002
Genetics of Parkinson's disease and biochemical studies of implicated gene productsPeter T Lansbury, Alexis Brice
Current Opinion in Genetics & Development|June 22, 2002
Genetics of Parkinson's disease and biochemical studies of implicated gene productsPeter T Lansbury, Alexis Brice
Annual Review of Neuroscience|April 22, 2003
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystandersByron Caughey, Peter T Lansbury
Newsweek|December 27, 2005
Your health in the 21st century. A fix for faulty proteinsPeter T Lansbury, Tom Fagan
Quarterly Reviews of Biophysics|September 19, 2006
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?Hilal A Lashuel, Peter T Lansbury
Biochemistry|April 3, 2002
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanismMichael J Volles, Peter T Lansbury
Biochemistry|July 2, 2003
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's diseaseMichael J Volles, Peter T Lansbury
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2004
A possible therapeutic target for Lou Gehrig's diseaseSoumya S Ray, Peter T Lansbury
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Nature Medicine|August 10, 2004
Back to the future: the 'old-fashioned' way to new medications for neurodegenerationPeter T Lansbury
Cell|August 23, 2006
Improving synaptic function in a mouse model of ADPeter T Lansbury
Current Opinion in Cell Biology|September 17, 2002
Genetics of Parkinson's disease and biochemical studies of implicated gene productsPeter T Lansbury, Alexis Brice
Current Opinion in Genetics & Development|June 22, 2002
Genetics of Parkinson's disease and biochemical studies of implicated gene productsPeter T Lansbury, Alexis Brice
Annual Review of Neuroscience|April 22, 2003
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystandersByron Caughey, Peter T Lansbury
Newsweek|December 27, 2005
Your health in the 21st century. A fix for faulty proteinsPeter T Lansbury, Tom Fagan
Quarterly Reviews of Biophysics|September 19, 2006
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?Hilal A Lashuel, Peter T Lansbury
Biochemistry|April 3, 2002
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanismMichael J Volles, Peter T Lansbury
Biochemistry|July 2, 2003
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's diseaseMichael J Volles, Peter T Lansbury
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2004
A possible therapeutic target for Lou Gehrig's diseaseSoumya S Ray, Peter T Lansbury
Pageof 5